ECRG4 suppressed the progression of breast cancer via modulating NFIC/PTEN and SHP2/PI3K/SP1 signaling
ECRG4 inhibits breast cancer progression by positively regulating NFIC/PTEN to suppress the SHP2/PI3K/SP1 signaling pathway. Targeting this signaling axis may provide a new strategy for breast cancer treatment.
Authors
- Dianbin Ning
- Xinyu Zhao (ORCID: https://orcid.org/0000-0002-5128-4424)
- Yusen Wei
- Dan Song
Institutions
- Hebei General Hospital (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1186/s40001-026-04009-4
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00